Clinical trials: HFpEF - Heart Failure With Preserved Ejection Fraction
Heart Failure With Preserved Ejection Fraction, Diabetes Mellitus, Type 2
Modulation of Circulating Levels of the Ketone Body 3-hydroxybutyrate in Patients With Type 2 Diabetes and Heart Failure With Preserved Ejection Fraction: Metabolic Effects. (KETO-HFpEF-Metabolic)
Heart failure (HF) is among the most common causes of death in patients with type 2 diabetes (T2D). Ketones, 3-hydroxybutyrate (3-OHB), have shown to have beneficial effects in patients with hearth failure with reduced ejection…
- Conditions
- Heart Failure With Preserved Ejection Fraction, Diabetes Mellitus, Type 2, Ketonemia
- Trial name
- NCT05159570
- Testing
- Ketone ester
- Where
- Denmark
- Volunteers
- 10 people
- Sponsor
- University of Aarhus
Heart Failure With Preserved Ejection Fraction
HEART Camp Connect: A Feasibility Study
This study builds on the tested and refined HEART Camp intervention which has been shown to improve long-term adherence to exercise in individuals diagnosed with heart failure.
- Trial name
- NCT05985395
- Testing
- HEART Camp Connect
- Where
- United States
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- University of Nebraska
Heart Failure
A Study to Assess the Reaction of Body for Four Different Formulations of AZD9977 (Part A) and Influence of Food and Lower Dose of a Selected Formulation (Part B) in Healthy Male Subjects
AZD9977 is an oral, selective mineralocorticoid receptor (MR) modulator. AZD9977 is a partial antagonist and partial agonist in reporter gene assays and has a different interaction pattern with the MR compared to eplerenone.
- Trial name
- NCT03804645
- Testing
- Treatment A, Treatment B, Treatment C
- Where
- United Kingdom
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Heart Failure, Diastolic
Stratified Treatment to Ameliorate Diastolic Left Ventricular Stiffness in Heart Failure With Preserved Ejection Fraction
A 35-week, single-center, prospective, double-blind, controlled, randomized, 2x2 crossover, interventional Phase II study, investigating the effect of treatment with dapagliflozin 10mg od on Left Ventricular distensibility in…
- Trial name
- STADIA-HFpEF (NCT04475042)
- Testing
- Dapagliflozin
- Where
- Netherlands
- Volunteers
- 26 people
- Sponsor
- Mariëlle Scheffer
Heart Failure With Preserved Ejection Fraction
The Relationship Between Blood Pressure and Arterial Stiffness in HFpEF Patients With Different Levels of Obesity
Heart failure with preserved ejection fraction (HFpEF) was considered as a heterogeneous disease with multi-organ and multi-system design, which is related to various complications, such as hypertension, obesity and…
- Trial name
- NCT04535726
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Chongqing Medical University
Heart Failure
Feasibility Trial of the DC Devices Interatrial Septal Device (IASD) System
The purpose of this study is to evaluate the safety and potential benefits of the interatrial septal defect (IASD) System in patients with heart failure with preserved ejection fraction.
- Trial name
- NCT01570517
- Testing
- IASD System
- Where
- 3 sites in Australia, Czechia and 1 more
- Volunteers
- 11 people
- Sponsor
- Corvia Medical
Heart Failure With Preserved Ejection Fraction
A Study to Evaluate Whether Macitentan is an Effective and Safe Treatment for Patients With Heart Failure With Preserved Ejection Fraction and Pulmonary Vascular Disease
This is a study to evaluate whether macitentan is an effective and safe treatment for patients with heart failure with preserved ejection fraction (HFpEF) and pulmonary vascular disease.
- Trial name
- SERENADE (NCT03153111)
- Testing
- Macitentan
- Where
- 95 sites in United States, Argentina and 15 more
- Volunteers
- 143 people
- Sponsor
- Actelion
Heart Failure
A Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD9977 in Japanese Healthy Participants With Single and Multiple Ascending Dose Administration
AZD9977 is an oral, selective mineralocorticoid receptor (MR) modulator. AZD9977 is a partial antagonist and partial agonist in reporter gene assays and has a different interaction pattern with the MR compared to eplerenone.
- Trial name
- NCT03801967
- Testing
- AZD9977
- Where
- United Kingdom
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Heart Failure
The Effects of Inspiratory Muscle Training in Patients With Heart Failure With Preserved Ejection Fraction
Previous studies have evaluated the effects of inspiratory muscle training in patiens with heart failure and reduced ejection fraction; nevertheless,no evidence endorse the therapeutic role of inspiratory muscle training in…
- Trial name
- NCT01707277
- Testing
- Inspiratory muscle training, Usual care
- Where
- Spain
- Volunteers
- 26 people
- Sponsor
- Fundación para la Investigación del Hospital Clínico de Valencia
Heart Failure With Preserved Ejection Fraction (HFpEF)
UK Heart Failure With Preserved Ejection Fraction
Heart failure occurs when the heart is no longer able to pump blood around the body properly. It can cause breathlessness, swollen feet and ankles, and tiredness.
- Trial name
- UK HFpEF (NCT05441839)
- Where
- 26 sites in United Kingdom
- Volunteers
- 10,000 people
- Sponsor
- Manchester University NHS Foundation Trust
Heart Failure, Heart Failure With Preserved Ejection Fraction (HFPEF)
Sodium-Glucose Cotransporter 2 Inhibitor Use in a National Heart Failure Telemonitoring Program
This observational cohort study evaluates temporal trends and determinants of sodium-glucose cotransporter 2 inhibitor (SGLT2i) prescriptions among adults with chronic heart failure enrolled in a nationwide remote monitoring…
- Conditions
- Heart Failure, Heart Failure With Preserved Ejection Fraction (HFPEF), Heart Failure With Reduced Ejection Fraction, Heart Failure With Mildly Reduced Ejection Fraction (HFmrEF)
- Trial name
- REMOTE-HF (NCT07022379)
- Testing
- SGLT2 Inhibitor Use
- Where
- France
- Volunteers
- 13,660 people
- Sponsor
- Satelia
Heart Failure, Acute Heart Failure
Pharmacological Optimization in Prevention in Heart Failure: A Sex-gap?
The goal of this clinical trial is to learn whether a rapid and intensive optimization of heart failure medications in women can improve outcomes after hospitalization for heart failure.
- Conditions
- Heart Failure, Acute Heart Failure, Heart Failure With Reduced Ejection Fraction (HFrEF), Heart Failure With Preserved Ejection Fraction (HFPEF)
- Trial name
- PopS-HF (NCT07295522)
- Testing
- Guideline-Directed Medical Therapy (GDMT)
- Where
- 12 sites in Italy
- Volunteers
- 368 people
- Sponsor
- IRCCS Policlinico S. Donato
Heart Failure With Preserved Ejection Fraction, Type 2 Diabetes
Remote Ischaemic Conditioning (RIC) in Heart Failure
This study will test the impact of remote ischaemic conditioning combined with exercise on myocardial perfusion in patients with or at risk of heart failure
- Conditions
- Heart Failure With Preserved Ejection Fraction, Type 2 Diabetes, Dilated Cardiomyopathy
- Trial name
- ENRICH (NCT06616233)
- Testing
- Remote Ischaemic Conditioning with exercise, Other: Remote Ischaemic Conditioning
- Where
- United Kingdom
- Volunteers
- 60 people
- Sponsor
- University of Leicester
Heart Failure
REALIsM-HF Pilot Study
The study aims to explore two marketed devices providing a multimarker monitoring including physical activity under real-life conditions in patients with heart failure with preserved ejection fraction (HFpEF) and with heart…
- Trial name
- REALIsM-HF (NCT03507439)
- Testing
- AVIVO Mobile Patient Management (MPM) System, VitalPatch biosensor, DynaPort Move Monitor
- Where
- 5 sites in United States, Germany and 1 more
- Volunteers
- 27 people
- Sponsor
- Bayer
Heart Failure With Preserved Ejection Fraction (HFPEF)
Copenhagen Heart Failure With Preserved Ejection Fraction
Heart failure with preserved ejection fraction (HFpEF) has grown to become the dominant form of heart failure (HF) worldwide, in tandem with ageing of the general population and the increasing prevalence of obesity, diabetes…
- Trial name
- CPH-HFpEF (NCT06685237)
- Where
- Denmark
- Volunteers
- 5,000 people
- Sponsor
- Tor Biering-Sørensen
Pulmonary Hypertension Secondary, Heart Failure
Oral Nitrite in Patients With Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction
The main objective of this study is to determine the clinical efficacy of oral inorganic nitrite verses placebo and the therapeutic response with regards to exercise tolerance in patients with pulmonary hypertension and heart…
- Trial name
- PH-HFpEF (NCT03015402)
- Testing
- Sodium Nitrite
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- University of Pittsburgh
Heart Failure With Preserved Ejection Fraction
Biomarkers in HF: Circulating Biomarkers of Fibrosis and Cardiovascular Disease
Heart failure with preserved ejection fraction (HFpEF) represents one of the largest unmet needs in cardiovascular medicine. Heart muscle scarring (myocardial fibrosis) is a key HFpEF disease mechanism and represents an important…
- Trial name
- NCT05826821
- Testing
- Pirfenidone
- Where
- United Kingdom
- Volunteers
- 107 people
- Sponsor
- Manchester University NHS Foundation Trust
Heart Failure
A Study to Learn About the Study Medicine Called PF-07328948 in Adults With Heart Failure (BRANCH-HF)
The purpose of this study is to learn about the safety and effects of the study medicine (PF-07328948) for the possible treatment of heart failure (HF).
- Trial name
- NCT06991257
- Testing
- Low Dose PF-07328948, Medium Dose PF-07328948, High Dose PF-07328948
- Where
- 150 sites in United States, Argentina and 12 more
- Volunteers
- 620 people
- Sponsor
- Pfizer
Heart Failure, Heart Failure With Preserved Ejection Fraction (HFPEF)
Colchicine in Patients With Heart Failure With Preserved Ejection Fraction and Inflammation
The main purpose of the CHIPS trial is to evaluate the efficacy and safety of colchicine in heart failure with preserved ejection fraction (HFpEF) patients with inflammation, including the effects of colchicine on circulating…
- Conditions
- Heart Failure, Heart Failure With Preserved Ejection Fraction (HFPEF), Chronic Inflammation, Inflammation
- Trial name
- CHIPS (NCT06604611)
- Testing
- Colchicine 0.5 MG Oral Tablet Once Daily
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Dongying Zhang
Acute Myocardial Infarction, Heart Failure With Preserved Ejection Fraction
Predictors and Outcomes of In-hospital HFpEF in AMI Patients
This retrospective observation is to investigate the incidence,clinical outcomes and prognosis of hospitalized heart failure with preserved ejection fraction (HFpEF) in patients with acute myocardial infarction(AMI).
- Conditions
- Acute Myocardial Infarction, Heart Failure With Preserved Ejection Fraction, Predictor, Prognosis
- Trial name
- NCT03351179
- Testing
- clinical characteristics, previous history, laboratory bio-markers, echocardiographic measurements, angiographic findings,clinical outcomes
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Xiangjun Yang